Lillian Siu

68PUBLICATIONS
398CO-AUTHORS
Tumour immunologyApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (68)

|Oct 29, 2026
A First-in-Human, Phase I Trial of MK-6598, an Inhibitor of the Immune Checkpoint IL4I1, With or Without Pembrolizumab for Advanced Solid Tumors.

|Oct 23, 2026
Bispecific dual T cell agonist invikafusp alfa in solid tumors: the phase 1/2 START-001 trial.

|Oct 20, 2026
Comparative analysis of ovarian cancer tumor-infiltrating T cells with those in melanoma and before and after PD-1 blockade.

|Aug 27, 2026
A Phase I First-Time-in-Human, Open-label Study of Nelistotug Administered to Patients with Advanced Solid Tumors.

|Aug 26, 2026
EphA4 Mediates Protumoral and Antitumoral Effects through Upstream Negative Regulation of AKT in Head and Neck Squamous Cell Carcinoma.

|Aug 13, 2026
Immune Checkpoint Blockade Sensitivity Is Linked to Endogenous Retroelement Transcriptional Changes in Cancer.

Pageof 12

Frequent Collaborators

15 joint publications

Anna Spreafico

13 joint publications

Philippe L Bedard

10 joint publications

Scott V Bratman

9 joint publications

Aaron R Hansen